The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Bayesian optimal interval designs for phase I clinical trials
Abstract
In phase I trials, effectively treating patients and minimizing the chance of exposing them to subtherapeutic and overly toxic doses are clinicians' top priority. Motived by this practical consideration, we propose Bayesian optimal interval (BOIN) designs to find the maximum tolerated dose and to minimize the probability of inappropriate dose assignments for patients. We show, both theoretically and numerically, that the BOIN design not only has superior finite and large sample properties but also can be easily implemented in a simple way similar to the traditional ‘3+3’ design. Compared with the well-known continual reassessment method, the BOIN design yields comparable average performance to select the maximum tolerated dose but has a substantially lower risk of assigning patients to subtherapeutic and overly toxic doses. We apply the BOIN design to two cancer clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
O'Quigley, J., Pepe, M., & Fisher, L. (1990) · Biometrics · doi:10.2307/2531628 · Cited by 1,577
Statistical Inference Under Order Restrictions
Kalbfleisch, J. D. (1975) · Technometrics · doi:10.1080/00401706.1975.10489288 · Cited by 1,546
Design and Analysis of Phase I Clinical Trials
Storer, B. E. (1989) · Biometrics · doi:10.2307/2531693 · Cited by 930
Statistical inference under order restrictions
(1973) · Statistica Neerlandica · doi:10.1111/j.1467-9574.1973.tb00228.x · Cited by 820
Critical aspects of the Bayesian approach to phase I cancer trials
Neuenschwander, B., Branson, M., & Gsponer, T. (2008) · Statistics in Medicine · doi:10.1002/sim.3230 · Cited by 439
A comparison of two phase I trial designs
Korn, E. L., Midthune, D., Chen, T. T., Rubinstein, L. V., Christian, M. C., & Simon, R. M. (1994) · Statistics in Medicine · doi:10.1002/sim.4780131802 · Cited by 303
A modified toxicity probability interval method for dose-finding trials
Ji, Y., Liu, P., Li, Y., & Nebiyou Bekele, B. (2010) · Clinical Trials · doi:10.1177/1740774510382799 · Cited by 273
Model calibration in the continual reassessment method
Lee, S. M., & Cheung, Y. K. (2009) · Clinical Trials · doi:10.1177/1740774509105076 · Cited by 225
Dose Finding in Drug Development
(2006) · Statistics for Biology and Health · doi:10.1007/0-387-33706-7 · Cited by 224
Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials
Lin, Y. (2001) · Biostatistics · doi:10.1093/biostatistics/2.2.203 · Cited by 171
Cited by
Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials
(2016) · doi:10.1158/1078-0432.ccr-16-0592 · Cited by 235
Current status of Bayesian clinical trials for oncology, 2020
Fors, M., & González, P. (2020) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2020.100658 · Cited by 18
Metadata
- Authors
- Liu, S., & Yuan, Y.
- Venue
- Journal of the Royal Statistical Society: Series C (Applied Statistics)
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-12-05
- Volume
- 64
- Issue
- 3
- Pages
- 507-523
- ISSN
- 0035-9254 (ISSN-L)
- OpenAlex
- W1988289042
- Cited by
- 350
- References
- 18
- FWCI
- 9.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.